Aldeyra Therapeutics Completes Enrollment for Phase 2 trial of ADX-2191 for Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. has announced the completion of the enrollment process for the Phase 2 Clinical Trial of ADX-2191 (methotrexate injection, USP), a potential treatment for retinitis pigmentosa. The trial enrolled 8 patients with rhodopsin gene mutations, including the P23H gene mutation, and aims to assess the safety of the drug as the primary endpoint. The secondary endpoints of the trial include the evaluation of changes from baseline in visual acuity, retinal function as evaluated by foveal microperimetry, dark adaptation, and electroretinography, as well as retinal morphology as assessed by optical coherence tomography.

Publish Date: 16-03-2023 Source: Aldeyra Therapeutics, Inc.

Retinitis pigmentosa (RP) is an inherited retinal degeneration characterised by nyctalopia and progressive visual field loss, eventually leading to blindness. The primary defect usually lies in the rod photoreceptors, which gradually degenerate. Secondary cone cell death follows, presumably due to oxidative damage and cone starvation. The age of onset of symptoms is the most variable factor. This can vary not only between families but also within subtypes of RP. However, after that, the rate and modality of progression tend to follow a fairly predictable and stereotyped exponential pattern. There is no curative therapy for retinitis pigmentosa. However, patients who happen to be taking vitamin A, vitamin E, or both were recorded to have slower declines in ERG amplitudes than those not taking such supplements.

RP affects about 25 to 30 cases per 100,000 population globally. In the United States, about 128,500 people were diagnosed with RP in 2019, reaching up to 156,750 by 2030.
In the EU5, about 108,250 people were diagnosed with RP in 2019, and the number will reach up to 136,450 by 2030.

However, the current Retinitis Pigmentosa (RP) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (AAV5-RPGR, Aflibercept, CPK850, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Retinitis Pigmentosa treatment. The key companies in the advanced development stage are MeiraGTx UK II Ltd, Bayer, Novartis Pharmaceuticals, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Retinitis pigmentosa (RP) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.